ViiV Healthcare Announces FDA Approval For HIV Drug For Children

ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced that the U.S. Food and Drug Administration (FDA) has approved Tivicay PD (dolutegravir) tablets for oral suspension. They are used in combination with other antiretroviral agents for the treatment of HIV-1 infection in children aged at least four weeks and weighing at least 3kg, as well as an extended indication to expand the use of the already approved Tivicay (dolutegravir) 50mg film-coated tablet in children with HIV weighing 20kg and above.

Paediatric HIV remains a global issue . . .